Research shows prostate drug market to double
Waltham-based research firm Decision Resources reported today that the launch of nine emerging therapies will help to drive the prostate cancer drug market to more than double to $8.4 billion a year by 2019 in major markets.
In its Pharmacor 2010 report Decision Resources estimated that sales of emerging therapies, most notably Dendreon’s Provenge, will account for 57 percent of the total prostate cancer market in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. In addition to Provenge, market growth will be driven by the uptake of Sanofi-Aventis’s Jevtana, AstraZeneca’s zibotentan, Johnson & Johnson’s abiraterone, Amgen/GlaxoSmithKline/Daiichi Sankyo’s Prolia, Medivation/Astellas Pharma’s MDV-3100, Algeta/Bayer Schering Pharma’s Alpharadin, Bristol-Myers Squibb’s Sprycel and Celgene’s Revlimid.
Provenge gained approval in the U.S. earlier this year.